Jocher, Georg https://orcid.org/0000-0002-7089-3487
Grass, Vincent https://orcid.org/0000-0001-7710-4789
Tschirner, Sarah K
Riepler, Lydia https://orcid.org/0000-0002-7879-5566
Breimann, Stephan https://orcid.org/0000-0002-0305-3373
Kaya, Tuğberk
Oelsner, Madlen
Hamad, M Sabri https://orcid.org/0000-0002-3684-6388
Hofmann, Laura I
Blobel, Carl P https://orcid.org/0000-0001-5053-3137
Schmidt‐Weber, Carsten B https://orcid.org/0000-0002-3203-8084
Gokce, Ozgun
Jakwerth, Constanze A
Trimpert, Jakob https://orcid.org/0000-0003-1616-0810
Kimpel, Janine https://orcid.org/0000-0002-5210-7905
Pichlmair, Andreas https://orcid.org/0000-0002-0166-1367
Lichtenthaler, Stefan F https://orcid.org/0000-0003-2211-2575
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (390857198)
Deutsche Forschungsgemeinschaft (PI1084/3)
Deutsche Forschungsgemeinschaft (PI/1084/4)
Deutsche Forschungsgemeinschaft (PI/1084/5)
Deutsche Forschungsgemeinschaft (TRR179/TP11)
Deutsche Forschungsgemeinschaft (TRR237/A07)
Bundesministerium für Bildung und Forschung (ESCAPE (01KI20169A))
Bundesministerium für Bildung und Forschung (COVINET‐01KI2050A)
Bundesministerium für Bildung und Forschung (JPND PMG‐AD‐01ED2002B)
Bundesministerium für Bildung und Forschung (FKZ161L0214C)
EC | ERC | HORIZON EUROPE European Research Council (817798)
Bayerisches Staatsministerium für Bildung und Kultus, Wissenschaft und Kunst (ForCOVID/TP7)
Article History
Received: 10 November 2021
Revised: 7 April 2022
Accepted: 12 April 2022
First Online: 8 May 2022
Disclosure and competing interests statement
: The authors declare that they have no conflict of interest. Dr. Blobel holds a patent on a method of identifying agents for combination with inhibitors of iRhoms. Dr. Blobel and the Hospital for Special Surgery have identified iRhom2 inhibitors and have co‐founded the start‐up company SciRhom in Munich to commercialize these inhibitors.